Catalyst
Slingshot members are tracking this event:
Concert Pharma (CNCE) Initiates Phase 2 Study of AVP-786 as Adjunctive Treatment on Major Depression Disorder (Note: Study Abandoned)
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
This study is currently recruiting participants.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 01, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2 Study, Avp-786, Adjunctive Treatment, Major Depressive Disorder
